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Alum Ochsner Medical Institutions, Renal Division, Department of Internal Medicine, New Orleans, Louisiana, USA
Treatment of arterial hypertension in diabetic humans: Importance of
therapeutic selection. This study was undertaken to test the hypothesis
that, given equal arterial pressure reductions, the combination of an
angiotensin converting enzyme (ACE> inhibitor and calcium antagonist
slows declines in renal function and yields greater reductions in
albuminuria over either agent alone. This hypothesis was evaluated in
four groups of hypertensive, non-insulin dependent, diabetic subjects
with renal insufficiency (N = 30). Renal hemodynamics, albuminuria
and metabolic parameters were evaluated for a period of one year.
Subjects were all placed on a 90 mEq sodium, 0.8 g/kg protein, 1500
calorie American Diabetes Association diet for the entire length of the
study. Subjects were followed for two weeks off antihypertensive
medications and were subsequently randomized to either lisinopril,
alone (group I), sustained release verapamil, alone (group H), reduced
doses of both lisinopril and sustained release verapamil (group III), and
hydrochlorothiazide with guanfacine (group IV). At the end of one year
group III had the greatest reduction in albuminuria (78 7%, group III
vs. 59% 4, group I: P < 0.05). In addition, the decline in glomerular
filtration rate (GFR) was the lowest in this group (0.28 0.07, group HI
vs. 0.69 0.12, group I; P < 0.05) although there was no significant
difference between groups II and IV. The highest side effect profiles
were noted in group IV, the least in group III. The greatest reductions
in renal hemodynamics occurred in all groups within the first month;
however, striking differences between groups were noted (7.4 2%,
group I vs. 1.4 2%, group III; P < 0.05). We conclude that the
combination of reduced doses of an ACE inhibitor and calcium antag-
onist attenuate both albuminuria and the rate of decline in glomerular
filtration rate. Furthermore, the combination of these classes of agents
appear to yield the lowest side effect profile over either agent alone.
Lastly, high doses of ACE inhibition alone may be detrimental to renal
function in late stage diabetics with renal insufficiency.
A number of studies utilizing animal models of diabetes
demonstrate that angiotensin converting enzyme (ACE) inhib-
itors lower glomerular capillary pressure and attenuate devel-
opment of glomerulosclerosis [1—3]. In addition, these and other
studies report reductions in urinary protein excretion, a well
described marker for progression of diabetic renal disease in
humans [1—8]. The mechanism, however, by which this class of
antihypertensive agents reduces both proteinuria and progres-
sion of diabetic renal disease is unclear.
Angiotensin II is purported to have a role in mediating both
the abnormal renal hemodynamic and cellular responses seen in
diabetic nephropathy [2, 9—11]. Furthermore, a marked in-
crease, above controls, in vascular reactivity to infusion of
angiotensin II in diabetic subjects is dependent upon sodium
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intake [11]. Moreover, angiotensin II is known to mediate both
its renal hemodynamic and cellular effects largely through
increases in cytosolic free calcium 112—14]. Thus, alterations in
calcium signaling by means of calcium channel antagonists may
result in similar renal hemodynamic and antiproteinuric effects
to those seen with ACE inhibitors.
Calcium antagonists have been shown to partially inhibit the
renovascular hemodynamic response to angiotensin II infusion
[15—17]. Animal studies demonstrate that angiotensin II induced
vasoconstriction is attenuated by the calcium antagonists, ver-
apamil and diltiazem [18, 19]. This partial inhibitory response is
primarily seen at the afferent arteriole. Additional studies on an
isolated perfused kidney preparation pretreated with the ACE
inhibitor, captopril, demonstrate that non-hypotensive doses of
the calcium antagonists, verapamil and diltiazem, result in
further reductions in efferent arteriolar resistance over ACE
inhibition alone [20]. This reduction in efferent arteriolar resis-
tance, however, was statistically significant only when vera-
pamil was added.
Recent studies in animal models of hypertension demonstrate
similarities in renal hemodynamic and antiproteinuric responses
of certain classes of calcium antagonists with those seen with
ACE inhibitors 12 1—23]. Specifically, the papaverine (vera-
pamil) and benzothiaprine (diltiazem) derivative calcium antag-
onists lower glornerular capillary pressure to a lesser, but
similar, extent compared to ACE inhibitors. Conversely, the
dihydropyridine compounds lack this effect [24, 251. Further-
more, four separate human studies in diabetic subjects describe
reductions in urinary protein excretion with certain calcium
antagonists [26—291.
Taken together these studies support the notion that addition
of a calcium antagonist, which lowers glomerular capillary
pressure, to an ACE inhibitor will lead to further reductions in
urinary albumin excretion and perhaps better preserve renal
function. The hypothesis is thus put forth that by further
reducing intraglomerular pressure, the combination of a cal-
cium antagonist and ACE inhibitor will result in greater reduc-
tions in urinary protein excretion and preservation of renal
function over either agent alone. This study investigates the
renal hemodynamic and antiproteinuric effects of a calcium
antagonist, verapamil, and ACE inhibitor, lisinopril, alone and
in combination in three groups of non-insulin dependent dia-
betic subjects with documented nephrotic range proteinuria,
hypertension, and renal insufficiency. These groups were com-
pared to a control group of diabetic, hypertensive subjects with
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Table 1. Baseline parameters of population studied
Groups
Study Control(N=24) (N=6)
I. Demography and history
Sex male/female 15/9 4/2
Race black/white 14/10 5/1
Weight kg 88 5 92 7
Age years 57 1 59 2
Duration of diabetes years 14 4 12 3
Duration of hypertension years 15 6 16 2
II. Systemic and renal
Mean arterial pressure mm Hg 120 3 117 2
Serum creatinine p.jnol/liter 154 8 152 7
Serum urea nitrogen mmol/liter 13 2 15 3
Creatinine clearance mi/mm 74 2 71 3
Urinary sodium excretion mmol/day 168 12 181 16
Proteinuria glday 5.9 0.3 5.1 0.5
III. Metabolic
Plasma glucose concentration 9.8 0.3 9.6 0.4
mmol/liter
Hemoglobin A1C % 7.4 0.6 8.2 0.5
Cholesterol (total) mmol/liter 7.8 0.2 7.5 0.3
HDL mmol/liter 1.04 0.02 0.99 0.03
Serum albumin g/liter 26 1 28 2
All patients had documented diabetic retinopathy as assessed by
ophthalmologic examination; All data are presented as mean stan-
dard error of the mean. Abbreviation HDL is high density lipoprotein.
renal insufficiency that received conventional antihypertensive
therapy. The analysis of data from these groups of subjects
form the basis of this report.
Methods
Thirty-four non-insulin dependent diabetic subjects with doc-
umented diabetic retinopathy were initially enrolled in the
study. Thirty subjects (19 males and 11 females) between the
ages of 48 and 64 years of age with mild hypertension (mean
arterial pressure  106 131 mm Hg), nephrotic range protein-
uria (3.5 g/day, urinary protein) and mild renal insufficiency
(serum creatinine  123 168 mol/1iter) completed the study.
To eliminate other diseases that may affect proteinuria and
glomerular function, all subjects with problems such as cardiac,
pulmonary or collagen vascular diseases, gout, multiple my-
eloma or amyloidosis were excluded by appropriate laboratory
tests or subcutaneous fat pad biopsy prior to the study. All
subjects had dietary counseling by a renal dietician and oph-
thalmologic examination to assess the degree of diabetic reti-
nopathy prior to inclusion in the study. In all cases, subjects
had proliferative diabetic retinopathy and required laser ther-
apy. In addition, subjects were instructed on, and received, 90
mEq sodium, 0.8 g!kg protein, 1500 calorie American Diabetes
Association diet for two weeks prior to antihypertensive drug
randomization. They remained on this diet for the duration of
the study.
The baseline demographic and laboratory parameters of all
subjects including the control group are summarized in Table 1.
All anti-hypertensive medications in all groups were stopped
two weeks prior to enrollment in the study. People with poor
blood sugar control, that is, fasting blood glucoses l6.5
mmol/liter, or those with poor arterial pressure control, that is,
a mean arterial pressure of >132 mm Hg were excluded from
the study. All subjects were maintained on oral hypoglycemic
agents; none received insulin on a continual basis during this
study. Arterial pressure was performed by the same individual
and repeated in duplicate in both the supine and upright
postures using a standard sphygmomanometer on the left arm.
The study design and timing of all blood pressure measure-
ments and laboratory values are illustrated in Figure 1. All
subjects were randomized to one of four study groups after
baseline data collection was completed: group I (lisinopril,
alone), group II (sustained release verapamil, alone), group III
(a reduced dose of both lisinopril and sustained release vera-
pamil), and group IV [hydrochlorothiazide (HCTZ) and guan-
facine]. Each group had individual drugs titrated during the first
week to lower mean arterial pressure to 100 mm Hg. There-
after, blood pressure values were determined weekly with each
drug titrated for blood pressure control to the value previously
mentioned for a total of one year.
Baseline measurements for the following parameters were
obtained at the end of the two week period off antihypertensive
medication: glomerular filtration rate (GFR) by infusion of tech-
netium-99 labeled diethylene triaminepentaacetic acid (Tc-
DTPA), renal blood flow (RBF), by '311-paraaminohippurate,
complete blood count, lipid profile [total cholesterol and high
density lipoprotein cholesterol (HDL)], chemistry profile which
included serum creatinine, blood urea nitrogen, electrolytes,
blood glucose, glycosylated hemoglobin (HbA1C) measured by
Diamat high performance liquid chromatography (BioRad, Her-
cules, California, USA) and serum albumin. All subjects had
captopril renal scans to eliminate the possibility of renal artery
stenosis. 99Tc-DTPA clearances were calculated based on isotope
decay curves utilizing urine and blood values.
All laboratory and renal hemodynamic studies were per-
formed during the hours of 0800 and 1400 in all subjects. Results
of GFR were corrected to 1.73 m2 body surface area, using the
area at entry into the study. If significant weight loss occurred
(>5% initial weight) during the study values were recalculated.
All laboratory investigations were performed at the Alton
Ochsner Medical Foundation laboratory. All renal hemody-
namic studies were performed in the Nuclear Medicine Division
of the Ochsner Clinic. In addition, urinary studies consisted of
a twenty-four-hour urine collection for total protein, albumin,
creatinine, sodium and creatinine clearance. Following these
baseline measurements, glomerular filtration rate, renal blood
flow, lipid profiles and glycosylated hemoglobin were measured
monthly, while all other studies were performed weekly. No
studies were performed during the titration phase of the study.
Four subjects failed to complete the study. One subject in group
I dropped out because of a significant unrelieved cough. No
significant side effects prevented completion of any other sub-
ject in any other group. Three other subjects were terminated
from the study secondary to problems with blood glucose,
dietary noncompliance or both.
Statistical evaluation
All data are expressed as mean plus or minus standard error
of the mean unless otherwise specified. Data analyses were
performed on all monthly values of renal hemodynamics and
urinary albumin excretion utilizing a Student's t-test for inde-
pendent groups as well as analysis of variance to evaluate
differences between and within groups. The rate of decline in
914 Bakris et a!: Arterial hypertension treatment
i,_Titratjon .••.i phase
I Group I (N = 8)
[Lisinopril]
Group II (N = 8)
[Verapamil SRI
Group Ill (N = 8)
1 [Lisinopril and
' Verapamil SR]
Group IV (N = 6)I — — —
[HCTZ, Guanfacinej
Maintenance
phase
Table 2. Renal hemodynamic changes following one year of arterial
pressure treatment in 30 type II diabetic patients
GFR
MAP mi/mini RBF UprotjnV
mm Hg 1.73 m2 mi/mm g/day
Group I (N = 8)
Baseline 116 2 70 3 373 8 5.9 0.4
Lisinopril 97 3 61 3 344 9 2.5 0.2
Group II (N = 8)
Baseline 121 2 65 2 362 6 5.7 0.3
Verapamil 96 2a 62 3 354 10 2.9 o.2
(sustained release)
Group III (N 8)
Baseline 122 3 67 2 361 8 6.8 0.5
Lisinopril plus 95 2 64 2 349 12 1.7 0.3
verapamil
(sustained release)
Group IV (N 6)
Baseline 117 2 68 2 363 8 5,1 0.5
HCTZ plus 96 3 63 3 351 13 4.5 0.4
guanfacine
P < 0.05 significantly different from baseline
GFR (mm/mm/month/i .73 m2) as well as the rate of decline in
albuminuria was calculated by linear regression analysis (least
square method). The ratio in the rate of decline in albuminuria
per rate of decline in GFR over time among the four groups was
assessed by analysis of variance. Comparisons between creat-
mine clearance and glomerular filtration rate corrected for body
surface area were also compared by analysis of variance. Side
effects were compared by the Wilcoxon signed rank test.
Statistical significance was defined as P < 0.05.
Results
Renal hemodynamics
A summary of all baseline renal and systemic hemodynamic
parameters is presented in Table 2. No significant differences
were noted between groups with regard to age, weight, duration
of diabetes or hypertension (Table 1). Likewise, racial differ-
ences were not striking among the different groups. Over 50%
of groups II to IV were composed of Black subjects. Group I,
however, only had 37% Black subjects. Arterial pressure re-
ductions were not significantly different between groups (Table
2). Likewise, baseline GFR was not statistically different be-
tween groups regardless of measurement, that is, creatinine
clearance or 99Tc-DTPA. However, a significant difference
between baseline creatinine clearance and Tc-DTPA did exist
in all groups.
Table 2 summarizes the renal and systemic hemodynamic
effects of various antihypertensive agents at the end of one year
of therapy. Only group I (lisinopril) demonstrated a significant
reduction of 13% in GFR and a 9.1% reduction in renal blood
flow following one year of therapy. Furthermore, more than
half of this decline in renal hemodynamics and albuminuria
occurred following the first month of therapy (Fig. 2). Group I
also had the greatest increase in serum potassium (4.1 0.2
mmol/liter, baseline to 4.7 0.3 mmollliter, lisinopril; P < 0.05
units) when compared to the other groups that exhibited no
significant change.
Evaluation of serum creatinine over the one year period
demonstrated no significant change in any of the four groups.
Group I, however, showed the greatest increase in serum
creatinine (151 6, baseline vs. 157 5 molIliter, lisinopril; P
= 0.23). The change in serum creatinine in this group at the end
of one year was only 4 1% as compared to a 15 2%
reduction in creatinine clearance and 13 1% reduction in
99Tc-DTPA. Similar differences were noted in the other groups.
Thus, serum creatinine appears to be the least sensitive indica-
tor of change in renal function in patients with diabetes and
renal insufficiency.
The rate of decline in GFR in each group over this time period
is summarized in Figures 3 and 4. Clearly, the most significant
declines were seen within the first few months of therapy in all
groups, with the greatest reduction in GFR seen in group I (Fig.
3). Furthermore, groups II and III had significantly lower rates
of decline in GFR as compared to group I (Fig. 4), This
statistical difference between group I and other groups, how-
ever, is eliminated if the first two months of data are omitted
from group I (0.38 0.13, group I vs. 0.28 0.07, mLlminl
month/1.73 m2 group III; P < 0.14). Since there was a stabili-
zation of glomerular filtration rate following this initial two
month period of decline in all groups, this type of analysis may
be more meaningful for long-term evaluation. When the first
two month data points in groups I through IV, with regard to
decline in glomerular filtration rate were eliminated, and the
Baseline
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Fig. 1. An illustrated protocol evaluating the
effects of different antihypertensive regimens
on diabetic renal disease. * Renal
hemodynamics (GFR, renal blood flow) and
lipoprotein profiles measured. Blood glucose
and arterial pressure were measured weekly
except during titration phase.
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Fig. 3. The monthly rate of decline in GJR corrected for body surface
area. Symbols are: (A) lisinopril alone; (A) sustained release verapamil
alone; (•) combined low dose sustained release verapamil and lisino-
pril; (0) hydrochlorothiazide plus guanfacine.
remaining data compared, there were no significant differences
between groups I through III. However, group IV clearly had
the fastest rate of decline of renal function when compared to
other groups, especially group III (0.21 0.09, group III vs.
0.48 0.04 mllmin/month/1.73 m2, group IV; P < 0.05).
Protein uria
Urinary protein excretion was significantly reduced in all but
group IV (Table 2). Following one year of therapy, the greatest
I H HI IV
Fig. 4. The mean decline in GFR (mi/mm/month/I .73 m2)following one
yearofantihypertensive therapy plus individual values in each offour
groups of diabetic subjects. Groups are: (I) lisinopril alone; (II) sus-
tained release verapamil alone; (III) combination low-dose sustained
release verapamil and lisinopril; (IV) hydrochlorothiazide plus
guanfacine.
reduction in urinary albumin excretion among all groups oc-
curred in group III (68 6%, group III vs. 8 3%, group IV;
P < 0.05). During this same period groups I and II had 55 and
47% reduction in urinary albumin excretion, respectively.
These were also statistically different from group III. The
greatest decline in urinary albumin excretion occurred during
the first month of treatment, Figure 2. Moreover, the slowest
rate of decline in urinary albumin excretion occurred in group
IV (1.5 0.5 g/month/1.73 m2; P < 0.05) when this value was
compared to groups I, II and III (8.5 0.4 g/month/1 .73 m2, 7.1
0.5 g/month/1.73 m2 and 12.8 0.6 mg/month/l.73 m2),
respectively. A significant difference was also found in monthly
albuminuria between groups II and III, but not group I. This
difference may have been secondary to a significant initial
decline in renal hemodynamics seen in group I, thus affecting
the overall monthly urinary albumin excretion rate in that
group. To correct for this, we eliminated the first two months of
data and calculated the rate of decline in g!month of albuminuria
in all groups. The values for each group were as follows: 7.2
0.4, group I; 6.4 0.3, group II; 10.1 0.4, group III; 0.9 0.5
g/month/l .73 m2, group IV. No statistical difference was noted
between groups I through III with this correction, however,
group IV still remained the slowest in the rate of decline in
urinary albumin excretion rates. When the rate of change in
albuminuria (g/month) over the rate of change in GFR (mI/mini
month/l.73 m2) is plotted over time, it is clear that group III
with the slowest rate of decline in GFR had the highest rate of
reduction in urinary albumin excretion rate (Fig. 5). This
suggests that reduction in albuminuria may reflect preservation
of renal function.
Metabolic effects
The metabolic effects among the four groups of non-insulin
dependent diabetic subjects studied were only partially as-
sessed. Specifically, nitrogen balance could not be assessed in
these patients since we did not calculate it. However, urinary
sodium excretion and body weight along with plasma glucose
and glycosylated hemoglobins, serum albumin and other lipid
parameters were assessed on a fairly rigid schedule. During the
study, there were no significant differences noted in urinary
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Fig. 2. The percent change in GFR and albuminuria seen after one
month of treatment in each group of diabetic subjects. Symbols are:
open column—lisinopril alone; cross hatched column—sustained re-
lease verapamil; linear column—low doses of both sustained release
verapamil plus lisinopril; dotted columns—hydrochlorothiazide plus
guanfacine. * P < 0.05 compared to lisinopril alone; + compared to
sustained release verapamil; compared to low doses of sustained
release verapamil plus lisinopril.
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Fig. 5. The relationship between the rate of
change in GFR and albuminuria at one year.
Note the slower rate of decline in GFR the
greater the reduction in urinary albumin
excretion. Symbols are: (•) lisinopril alone;
______
(•) verapamil SR alone; (•) lisinopril plus
verapamil SR; (A) hydrochiorothiazide plus
guanfacine; (0) lisinopril alone corrected for
0.6 0.7 0.8 0.9 1.0 initial decline in GFR. * P < 0.05 significantlyslower rate of decline in GFR and greater
reduction in urinary albumin excretionG FR, rn//rn/n/month! 1.73 m2 compared to group IV.
sodium excretion or body weight. Urinary sodium excretion
reflected good compliance with the sodium restricted diet. The
range of urinary sodium throughout the study in all groups was
from 93 15 mmol/liter to 128 36 mmol/liter. At the
termination of the study the following urinary sodium values
were noted in each group: 96 11, group I; 103 8 mmol/liter,
group II; 108 7 mmoLlliter, group III; 98 9 mmollliter, group
IV. Body weight also remained relatively stable with the
exception of two subjects in group I who lost 7 and 9 pounds,
respectively, throughout the year. The increase in plasma
glucose noted in some individuals was also reflected by an
increase in glycosylated hemoglobin values in one year. How-
ever, there were no statistically different values in glycosylated
hemoglobin at the termination of the study between groups.
Serum albumin values were increased in groups I through III;
however, only group III showed a significant increase in this
value (27 2, baseline compared to 36 3 glliter; P < 0.05).
This group also exhibited a substantial decline in serum choles-
terol (7,6 0.3, baseline compared to 6.5 0.2 mmol/liter, one
year, P < 0.05). HDL values, however, were not significantly
affected in any group. The mean range of HDL values was 1.08
0.02 rnmollliter, group III to 0.99 0.03 mmol/liter in group
IV.)
Side effects
All side effects and drug dosage ranges are summarized in
Table 3. Group IV clearly had the most side effects of any
group, with group III exhibiting the fewest. Furthermore, the
incidence of constipation was significantly less in group III
when compared to group II (Table 3).
Discussion
We report the effects of a calcium antagonist and an ACE
inhibitor alone and in combination on renal hemodynamics,
albuminuria and the course of diabetic renal disease in patients
with hypertension and pre-existing renal insufficiency. These
data were compared to a control group of diabetic hypertensive
patients who received conventional antihypertensive therapy.
Our data support the notion that the combination of an ACE
inhibitor and the calcium antagonist, verapamil, appear to be
Table 3. Dosage and frequency of adverse effects after one month of
treatment
Dosage
mg Side effect?
Group I
Lisinopril 29 2 (10—40) Dizziness 3/8 (38)
Cough 1/8/(13)
Group II Constipation 7/8 (88)
Verapamil 362 21 (240—480) Fatigue 2/8/ (25)
(sustained release) Dizziness 1/8/(13)
Group III 16 2 (10...25)b Constipation 2/8 (25)C
Lisinopril plus 187 8 (180_240)b Fatigue 1/8 (13)
verapamil
(sustained release)
Group IV 19 3 (12.5—25) Dry Mouth 6/6 (100)
Hydrochlorothiazide 2 1 (1—3) Sleepiness 4/6 (67)
plus guanfacine Fatigue 3/6 (50)
Impotence 2/6 (34)
Dosage is given as a mean standard error with the range enclosed
in parentheses.
a Data are presented as number of patients with side effects in each
group, parentheses indicate percentage of patientsb Statistically significant lower dosage, when compared to groups I or
II, P < 0.05
Statistically significant lower side effect profile when compared to
group II, P < 0.05
superior over either agent alone or conventional therapy for
reducing urinary protein and albumin excretion in this popula-
tion. This reduction in urinary albumin excretion was most
exemplified in group III where it resulted in a 33% increase in
serum albumin over the one year period of the study. This was
much greater than in the groups that received either an ACE
inhibitor or calcium antagonist alone.
The combination of an ACE inhibitor and calcium antagonist
also led to the lowest rate of decline in renal function over
groups I and II. Furthermore, when this group was compared to
conventional antihypertensive therapy it had a statistically
slower rate of decline in glomerular filtration rate. Group III
also demonstrated the lowest side effect profile of any group.
One of the possible reasons for the differences noted in the
group which received conventional therapy compared to the
1*11
>
E
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5
0
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others is the Black/White ratio in this group. It is difficult to
assess the impact of this racial factor given the size of our
study. However, in all groups but group I, where 37% of the
subjects were Black, more than 50% of the subjects were Black.
Thus, we propose that low doses of an ACE inhibitor and a
calcium antagonist in combination provide the fewest side
effects, and perhaps the best renal hemodynamic profile in
diabetic patients with hypertension and renal insufficiency. The
rate of decline in glomerular filtration rate in our study is
comparable to those previously reported in treated insulin-
dependent diabetics [30—32]. Furthermore, the group that re-
ceived combination therapy had a rate of decline slightly below
that previously reported with triple therapy (that is, diuretic,
beta-blocker, and hydralazine) [30]. This may reflect an effect
beyond simple blood pressure control. Previous animal studies
report reductions in glomerular capillary pressure, proteinuria
and progression of renal disease with either an ACE inhibitor or
certain classes of calcium antagonists [1—8, 21—23]. A recent
animal study also reports augmentation of ACE-inhibitor-in-
duced efferent arteriolar dilatation with addition of non-hy-
potensive doses of the calcium antagonist, verapamil [201. We
thus propose that the renal hemodynamic changes seen in our
group receiving combination therapy may be the result of
additional reductions in intraglomerular pressure rather than
simple blood pressure reduction.
The greatest reduction in renal hemodynamics was seen in
group I that received only an ACE inhibitor, at relatively high
doses for the level of renal function. This initial decline in renal
function may simply be the result of blood pressure reduction;
however, data from group IV, which demonstrates similar
arterial pressure reduction, does not seem to support this
notion. Another possibility might be the presence of bilateral
renal artery stenosis; however, all subjects were screened and
found not to have this problem. Thus, we feel that the acute
reduction in renal function seen with relatively high doses of
ACE inhibition, given the level of renal function in this popu-
lation, is the result of acute hemodynamic changes which may
be the result of excessive efferent arteriolar dilatation previ-
ously described in animal models of hypertension and renal
insufficiency or poor renal reserve [33].
Previous studies also document exacerbation of pre-existing
renal insufficiency by ACE inhibitors [33—351. However, fol-
low-up studies in our population demonstrate a much slower
decline in GFR after the initial few months, although still
statistically greater than the other three groups. This is most
likely due to the following factors. First, the dosage required to
lower arterial pressure was higher than appropriate for the level
of renal function. Second, the significant reduction in efferent
arteriolar resistance reported in animal studies by this agent
may have resulted in significant declines in glomerular capillary
pressure in the remnant "intact nephrons." Thus, use of lower
doses of two different classes of agents known to have similar
renal hemodynamic effects may result in a greater beneficial
clinical effect in patients with diabetes and mild renal insuffi-
ciency.
Increases in urinary albumin excretion have long been her-
alded as a predictor for progression of diabetic renal disease
culminating ultimately in renal failure [8, 36—38]. Augmentation
of albuminuria has also been reported to predict excess mortal-
ity in this population [39, 401. Our data support previous studies
documenting reductions in urinary albumin excretion with the
use of an ACE inhibitor [3—8]. This study also supports the
notion that calcium antagonists, which lower glomerular capil-
lary pressure and consequently reduce albuminuria in animal
models of hypertension, have similar effects in diabetic humans
[26, 27, 41—43].
Reduction of sodium in the diet of diabetic animals has been
shown to lower glomerular filtration rate [441. Human studies
document the requirement of sodium restriction to adequately
lower urinary albumin excretion with ACE inhibitors as well as
lower blood pressure [45, 46]. Thus, low sodium diets which all
patients followed may have an added benefit above and beyond
blood pressure control with regard to renal preservation. The
design of our study, however, did not enable us to assess this
factor.
The further reduction of albuminuria utilizing the combina-
tion of an ACE inhibitor and calcium antagonist may result from
several factors. These classes of agents have been shown to
effect glomerular size and charge selectivity to dextran and
albumin molecules by alternating sieving coefficients [21, 47—
51]. They have also been shown to lower glomerular capillary
pressures, in part by effects on efferent arteriolar resistances
[1—3, 21—24]. This combination of factors, as well as alterations
in hydraulic permeability of the remaining intact nephrons"
may help account for the changes seen in our population, all of
whom had similar arterial pressure reductions.
Neither ACE inhibitors nor calcium antagonists have been
reported to alter serum cholesterol [52, 53]. In our study group,
however, group III showed a marked reduction in serum
cholesterol without a significant change in the HDL fraction.
Our study design did not enable us to assess the mechanism for
the differences seen in our groups. We feel that the significant
improvement in group III is probably secondary to the reduc-
tion in urinary albumin excretion rather than a specific effect on
cholesterol synthesis.
The lowest side effect profile among the three groups that
received either an ACE inhibitor or calcium antagonist was
seen in group HI where low doses of both medications were
given. This is in keeping with the Joint National Committee's
recommendation to use low doses of multiple antihypertensive
agents to minimize side effects [54]. Diuretics and centrally
acting aipha-agonists have long been known to have high
side-effect profiles [52, 55]. Our data also confirm these reports.
Lastly, diabetic patients have also been known to have
associated glomerular pathologies, such as, minimal change
disease, focal glomerular sclerosis, etc. We cannot eliminate
the possibility that in some patients, other glomerular patholo-
gies were present since renal biopsies were not performed.
However, we feel strongly that given the natural history and
course of diabetes in our population, the possibility of addi-
tional or concomitant glomerular diseases is remote.
In summary, the results of this study suggest that the com-
bination of low doses of both an ACE inhibitor, lisinopril, and
a calcium antagonist, verapamil, appear to provide the greatest
reduction in urinary albumin excretion with the lowest side-
effect profile over either agent alone. This combination further
resulted in the slowest decline in renal function over time; an
effect that correlated with reductions in albuminuria. The
mechanisms for the attenuated increase in albuminuria and
918 Bakris et a!: Arterial hypertension treatment
stowed decline in renal function are unclear. It appears, how-
ever, not to be solely due to hetnodynamic alterations, since
blood pressure was equally reduced in all groups and a more
rapid progression of renal disease was noted in group IV. Thus,
factors such as glomerular permselectivity, altered hydraulic
permeability, and sympathetic nervous system activation all
may have a role in progression of diabetic renal disease.
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